Nothing Special   »   [go: up one dir, main page]

MX2019006852A - Composiciones y metodos para modular el sistema inmunologico. - Google Patents

Composiciones y metodos para modular el sistema inmunologico.

Info

Publication number
MX2019006852A
MX2019006852A MX2019006852A MX2019006852A MX2019006852A MX 2019006852 A MX2019006852 A MX 2019006852A MX 2019006852 A MX2019006852 A MX 2019006852A MX 2019006852 A MX2019006852 A MX 2019006852A MX 2019006852 A MX2019006852 A MX 2019006852A
Authority
MX
Mexico
Prior art keywords
compositions
immune system
methods
modulating
modulate
Prior art date
Application number
MX2019006852A
Other languages
English (en)
Inventor
A Noonan Kimberly
Borrello Ivan
R Lutz Eric
Original Assignee
Windmil Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Windmil Therapeutics Inc filed Critical Windmil Therapeutics Inc
Publication of MX2019006852A publication Critical patent/MX2019006852A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4636—Immune checkpoint inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Las modalidades proporcionadas aquí se refieren a composiciones y métodos relacionados con proteínas quiméricas que se pueden usar para modular el sistema inmunológico de un sujeto y, por ejemplo, para tratar el cáncer.
MX2019006852A 2016-12-22 2017-12-21 Composiciones y metodos para modular el sistema inmunologico. MX2019006852A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662438106P 2016-12-22 2016-12-22
PCT/US2017/067830 WO2018119198A1 (en) 2016-12-22 2017-12-21 Compositions and methods for modulating the immune system

Publications (1)

Publication Number Publication Date
MX2019006852A true MX2019006852A (es) 2019-08-26

Family

ID=62627209

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006852A MX2019006852A (es) 2016-12-22 2017-12-21 Composiciones y metodos para modular el sistema inmunologico.

Country Status (10)

Country Link
US (1) US20190330306A1 (es)
EP (1) EP3525805A4 (es)
JP (1) JP2020512284A (es)
KR (1) KR20190096969A (es)
CN (1) CN110267666A (es)
AU (1) AU2017382243A1 (es)
CA (1) CA3038150A1 (es)
IL (1) IL266386A (es)
MX (1) MX2019006852A (es)
WO (1) WO2018119198A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017002852A (es) * 2014-09-04 2017-05-30 Univ Johns Hopkins Activacion de linfocitos que infiltran la medula en condiciones hipoxicas alternando con normoxicas.
CN107995913B (zh) 2015-05-18 2022-02-11 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
WO2018098365A2 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2022211376A1 (ko) * 2021-04-01 2022-10-06 주식회사 이뮤노로지컬디자이닝랩 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도
KR20220144000A (ko) * 2021-04-16 2022-10-26 주식회사 이뮤노로지컬디자이닝랩 Programmed death-ligand 1(PD-L1)에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도
KR20240005865A (ko) * 2021-05-07 2024-01-12 메디진 이뮤노테라피스 게엠바하 Prame 특이적 t 세포 수용체 및 키메라 공동 자극 수용체의 조합

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6334398B2 (ja) * 2011-07-29 2018-05-30 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア スイッチ共刺激受容体
US9573988B2 (en) * 2013-02-20 2017-02-21 Novartis Ag Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
WO2015048744A2 (en) * 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP4205749A1 (en) * 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
MX2017002852A (es) * 2014-09-04 2017-05-30 Univ Johns Hopkins Activacion de linfocitos que infiltran la medula en condiciones hipoxicas alternando con normoxicas.
WO2016090034A2 (en) * 2014-12-03 2016-06-09 Novartis Ag Methods for b cell preconditioning in car therapy
CN108064251A (zh) * 2014-12-19 2018-05-22 达纳－法伯癌症研究所公司 碳酸酐酶ix特异性嵌合抗原受体及其使用方法
BR112017018919A8 (pt) * 2015-03-05 2023-04-11 Hutchinson Fred Cancer Res Proteínas de fusão imunomoduladoras e seus usos
AU2016251687C1 (en) * 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
WO2016179319A1 (en) * 2015-05-04 2016-11-10 Cellerant Therapeutics, Inc. Chimeric antigen receptors with ctla4 signal transduction domains
MX2018000278A (es) * 2015-06-29 2018-03-08 Univ Johns Hopkins Terapia de receptores quimericos de puntos de control inmunitarios.
CN105153315B (zh) * 2015-10-09 2019-04-02 重庆精准生物技术有限公司 免疫抑制受体联合肿瘤抗原嵌合受体及其应用
CA3017036A1 (en) * 2016-03-23 2017-09-28 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Fusion proteins of pd-1 and 4-1bb

Also Published As

Publication number Publication date
IL266386A (en) 2019-06-30
WO2018119198A1 (en) 2018-06-28
US20190330306A1 (en) 2019-10-31
JP2020512284A (ja) 2020-04-23
AU2017382243A1 (en) 2019-05-02
CN110267666A (zh) 2019-09-20
CA3038150A1 (en) 2018-06-28
EP3525805A1 (en) 2019-08-21
EP3525805A4 (en) 2020-07-29
KR20190096969A (ko) 2019-08-20

Similar Documents

Publication Publication Date Title
MX2019006852A (es) Composiciones y metodos para modular el sistema inmunologico.
MX2019007030A (es) Composiciones y metodos para el tratamiento del cancer.
MX2019006598A (es) Celulas asesinas naturales modificadas geneticamente y sus usos.
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
MX2019007020A (es) Anticuerpos il-11.
PH12018500711A1 (en) Anti-pd1 antibodies and methods of use
SA518400222B1 (ar) أجسام مضادة لـ وتركيبات tim-3
MY186334A (en) Anti-her2 antibodies and immunoconjugates
EP4421094A3 (en) Targeted therapeutic agents and uses thereof
PH12016501411B1 (en) Bifunctional cytotoxic agents
SG10201804931QA (en) Anti-cll-1 antibodies and immunoconjugates
GEP20217326B (en) Constructs having a sirp-alpha domain or variant thereof
PH12016502142B1 (en) Anti-ptk7 antibody-drug conjugates
MY191581A (en) Anti-pd-1 antibodies
SG10201808259TA (en) Anti-jagged1 antibodies and methods of use
JOP20200022A1 (ar) مركبات حلقية لولبية وطرق تصنيعها واستخدامها
MX2018010971A (es) Compuestos y métodos para modular la tirosina cinasa de bruton.
PH12018502137A1 (en) Anti-complement factor bb antibodies and uses thereof
AU2018289493A1 (en) Methods for modulating regulatory T cells, regulatory B cells, and immune responses using modulators of the APRIL-TACI interaction
SG11201811429XA (en) Flow reactor
PH12020500372A1 (en) Spirocycle compounds and methods of making and using same
MX2017015127A (es) Particulas modificadas por carbohidratos y formulaciones en particulas para modular una respuesta inmunitaria.
SG10201808278TA (en) Polishing composition and polishing method
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
MX2021009993A (es) Metodos y dispositivos para localizar composiciones.